Potential health risks of complementary alternative medicines in HIV patients

HIV Medicine

Volumn 9, Issue 8, 2008, Pages 653-659

  Ladenheim, David ^a   Horn, O ^b   Werneke, U ^c,d   Phillpot, M ^e   Murungi, A ^e   Theobald, N ^e   Orkin, C ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c SUNDERBY HOSPITAL   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Adverse effects; Antiretroviral drugs; Drug interactions; Echinacea; Prevalence

Indexed keywords

ALOE VERA EXTRACT; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ANTIRETROVIRUS AGENT; ANTIRHEUMATIC AGENT; ASCORBIC ACID; BETA CAROTENE; BETA GLUCAN; CHINESE DRUG; COD LIVER OIL; CREATINE; ECHINACEA EXTRACT; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GLUCOSAMINE; GLUTAMINE; GLYCYRRHIZA EXTRACT; GRAPE SEED EXTRACT; HERBACEOUS AGENT; MELATONIN; MULTIVITAMIN; PRIMROSE OIL; PROBIOTIC AGENT; PSYCHOTROPIC AGENT; SELENIUM; SILYBUM MARIANUM EXTRACT; UBIDECARENONE; UNINDEXED DRUG; VITAMIN B GROUP;

ALTERNATIVE MEDICINE; ARTICLE; CROSS-SECTIONAL STUDY; DRUG ABSORPTION; DRUG INDICATION; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HEALTH HAZARD; HERBAL MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; OUTPATIENT DEPARTMENT; PATIENT COUNSELING; PHYSIOTHERAPY; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; UNITED KINGDOM;

ADJUVANTS, IMMUNOLOGIC; ANTI-RETROVIRAL AGENTS; COMPLEMENTARY THERAPIES; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; PLANTS, MEDICINAL; PREVALENCE; QUESTIONNAIRES; VIRAL LOAD;

EID: 52649181128     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00610.x     Document Type: Article

References (46)

1. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States - prevalence costs, and patterns of use. N Engl J Med 1993; 328: 246-252.
2. Eisenberg DM, Davis RB, Ettner SL et al. Trends in alternative medicine use in the United States, 1990-1997. JAMA 1998; 280: 1569-1575.
3. Standish LJ, Greene KB, Bain S et al. Alternative medicine use in HIV-positive men and women: Demographics, utilization patterns and health status. AIDS Care 2001; 13: 197-208.
4. Josephs JS, Fleishman JA, Gaist P, Gebo KA. Use of complementary and alternative medicines among a multistate, multisite cohort of people living with HIV/AIDS. HIV Med 2007; 8: 300-306.
5. Bica I, Tang AM, Skinner S et al. Use of complementary and alternative therapies by patients with human immunodeficiency virus disease in the era of highly active antiretroviral therapy. J Altern Complement Med 2003; 9: 65-76.
6. Hsiao AF, Wong MD, Kanouse DE et al. Complementary and alternative medicine use and substitution for conventional therapy by HIV-infected patients. J Acquir Immune Defic Syndr 2003; 33: 157-165.
7. Furler MD, Einarson TR, Walmsley S et al. Use of complementary and alternative medicine by HIV-infected outpatients in Ontario, Canada. AIDS Patient Care STDS 2003; 17: 155-168.
8. Wiwanitkit V. The use of CAM by HIV-positive patients in Thailand. Complement Ther Med 2003; 11: 39-41.
9. De Visser R, Grierson J. Use of alternative therapies by people living with HIV/AIDS in Australia. AIDS Care 2002; 14: 599-606.
10. Colebunders R, Dreezen C, Florence E, Pelgrom Y, Schrooten W, the Eurosupport Study Group. The use of complementary and alternative medicine by persons with HIV infection in Europe. Int J STD AIDS 2003; 14: 672-674.
11. Duggan J, Peterson WS, Schutz M, Khuder S, Charkraborty J. Use of complementary and alternative therapies in HIV-infected patients. AIDS Patient Care STDs 2001; 15: 159-167.
12. Barton SE, Hawkins DA, Jadresic DM, Gazzard BG. Alternative treatments for HIV infection. BMJ 1989; 298: 1519-1520.
13. Anderson W, O'Connor BB, MacGregor RR, Schwartz JS. Patient use and assessment of conventional and alternative therapies for HIV infection and AIDS. AIDS 1993; 7: 561-565.
14. Fawzi WW, Msamanga GI, Spiegelman D et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med 2004; 351: 23-32.
15. Fairfield KM, Eisenberg DM, Davis RB, Libman H, Phillips RS. Patterns of use, expenditures and perceived efficacy of complementary and alternative therapies in HIV-infected patients. Arch Intern Med 1998; 158: 2257-2264.
16. Astin JA. Why patients use alternative medicine. JAMA 1998; 279: 1548-1553.
17. Werneke U, Earl J, Seydel C, Horn O, Crichton P, Fannon D. Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 2004; 26: 408-413.
18. World Health Organization. WHO Expert Monographs on Selected Medicinal Plants, Vol 1. London: World Health Organization, 1999.
19. Block KI, Mead MN. Immune system effects of echinacea, ginseng, and astragalus: A review. Integr Cancer Ther 2003; 2: 247-267.
20. Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002; 34: 234-238.
21. Dalvi RR. Alterations in hepatic phase I and phase II biotransformation enzymes by garlic oil in rats. Toxicol Lett 1992; 60: 299-305.
22. Foster BC, Foster MS, Vandenhoek S et al. An in-vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 2001; 4: 176-184.
23. World Health Organization. Pharmaceuticals: Restrictions in Use and Availability. Update of the Sixth Issue Essential Drugs and Medicines Policy Quality Assurance and Safety: Medicines. London: World Health Organization, 2003.
24. Escher M, Desmeules J, Giostra E, Mentha G. Hepatitis associated with Kava, a herbal remedy for anxiety. BMJ 2001; 322: 139.
25. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R et al. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol 2000; 86: 250-256.
26. de Maat MM, Hoetelmans RM, Mathot RA et al. Drug interaction between St John's wort and nevirapine. AIDS 2001; 15: 420-421.
27. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort. Lancet 2000; 355: 547-548.
28. Hennessy M, Kelleher D, Spiers JP et al. St John's wort increases expression of P-glycoprotein: Implications for drug interactions. Br J Clin Pharmacol 2002; 53: 75-82.
29. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000; 7: 273-282.
30. Frye RF, Kroboth PD, Folan MM et al. Effect of DHEA on CYP3A-mediated metabolism of triazolam. Clin Pharmacol Ther 2000; 67: 109 [Abstract PI-82].
31. Sugiyama T, Shinozuka K, Sano A et al. Effects of various Ginkgo biloba extracts and proanthocyanidin on hepatic cytochrome P450 activity in rats. Shokuhin Eiseigaku Zasshi 2004; 45: 295-301.
32. Ohnishi N, Kusuhara M, Yoshioka M et al. Studies on interactions between functional foods or dietary supplements and medicines. I. Effects of Ginkgo biloba leaf extract on the pharmacokinetics of diltiazem in rats. Biol Pharm Bull 2003; 26: 1315-1322.
33. Yale SH, Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med 2005; 11: 433-439.
34. Gurley BJ, Gardner SF, Hubbard MA et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005; 22: 525-539.
35. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000; 7: 273-282.
36. Prasad GV, Wong T, Meliton G, Bhaloo S. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation 2002; 74: 1200-1201.
37. Ernst E. Herb-drug interactions: Potentially important but woefully under-researched. Eur J Clin Pharmacol 2000; 56: 523-524.
38. Dasgupta A, Okhuysen PC. Pharmacokinetic and other drug interactions in patients with AIDS. Ther Drug Monit 2001; 23: 591-605.
39. Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999; 19: 708-712.
40. Burger DM, Hugen PW, Aarnoutse RE et al. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther Drug Monit 2003; 25: 73-80.
41. Hoetelmans RM, Reijers MH, Weverling GJ et al. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998; 12: 111-115.
42. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15: 1192-1194.
43. Forsyth SF, French PD, Macfarlane E, Gibbons SE, Miller RF. The use of therapeutic drug monitoring in the management of protease inhibitor-related toxicity. Int J STD AIDS 2005; 16: 139-141.
44. Kent UM, Aviram M, Rosenblat M, Hollenberg PF. The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6 and 2C9. Drug Metab Dispos 2002; 30: 709-715.
45. Fugh-Berman H. Herb-drug interactions. Lancet 2000; 355: 134-138.
46. Slain D, Amsden JR, Khakoo RA, Fisher MA, Lalka D, Hobbs GR. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers. Pharmacotherapy 2005; 25: 165-170.